非瑟酮通过Nrf2/HO-1/GPX4通路抑制神经元铁死亡减轻脓毒症相关脑损伤
该研究将6-8周龄雄性SD大鼠随机分为假手术组、盲肠结扎穿孔(CLP)脓毒症模型组和非瑟酮预处理组,每组18只(12只观察生存率、6只检测指标)。非瑟酮组在CLP前以50 mg×kg⁻¹×d⁻¹灌胃非瑟酮溶液连续5天,溶媒为二甲基亚砜(DMSO),假手术组和CLP组给予同剂量DMSO,末次灌胃后2小时造模。结果显示非瑟酮预处理组神经反射评分、新物体辨别指数和开臂停留时间均显著高于CLP组,脑组织铁离子和丙二醛含量降低,TNF-α和S100β表达下调,Nrf2、HO-1和GPX4表达上调,海马神经元病理损伤减轻。作者结论为非瑟酮预处理可通过Nrf2/HO-1/GPX4通路抑制铁死亡、减轻脓毒症相关脑损伤。
要点
- 大鼠CLP脓毒症模型中,非瑟酮50 mg×kg⁻¹×d⁻¹灌胃预处理5天,末次灌胃后2小时造模。
- 非瑟酮组神经反射评分7.33±1.15 vs CLP组4.67±1.53,新物体辨别指数0.44±0.02 vs 0.32±0.04,开臂停留时间78.33±9.29 min vs 41.15±9.64 min,均P<0.05。
- 非瑟酮组脑组织铁离子151.27±14.90 μg/g vs CLP组224.69±17.64 μg/g,MDA 470.0±44.3 μmol/g vs 709.3±65.4 μmol/g,均降低且P<0.05。
- 非瑟酮组Nrf2/GAPDH 0.708±0.108 vs CLP组0.316±0.112,HO-1/GAPDH 0.694±0.022 vs 0.538±0.024,GPX4/GAPDH 0.620±0.170 vs 0.317±0.039,均升高且P<0.05。
- 术后第10天存活数:假手术组12只、CLP组3只、CLP+非瑟酮组7只。
适用人群与场景
- 6-8周龄雄性Sprague-Dawley(SD)大鼠。
- sham operation group(Sham组)、colonic ligation and puncture(CLP)诱导脓毒症模型组(CLP组)和非瑟酮预处理组(CLP+Fisetin组),每组18只(12只观察生存率、6只检测指标)。
处置流程与药物剂量
- CLP+Fisetin组在CLP前以非瑟酮溶液50 mg×kg⁻¹×d⁻¹灌胃连续5天,溶媒为二甲基亚砜(DMSO)。
- Sham组和CLP组给予同剂量DMSO。
- 末次灌胃后2小时建立CLP模型。
研究设计与关键结果
- 研究类型:动物实验;样本量:每组18只SD大鼠(12只观察生存率、6只检测指标)。
- 术后第10天存活数:Sham组12只、CLP组3只、CLP+Fisetin组7只。
- 与Sham组相比,CLP组神经反射评分、新物体辨别指数和开臂停留时间显著降低;HE染色显示海马神经元排列紊乱、胞质深染、核固缩、结构不清、神经元丢失和明显炎症;普鲁士蓝染色显示脑组织铁离子沉积;脑组织铁和MDA含量升高,TNF-α和S100β表达上调,Nrf2、HO-1和GPX4表达下调。
- 与CLP组相比,CLP+Fisetin组神经反射评分显著升高(7.33±1.15 vs 4.67±1.53),新物体辨别指数改善(0.44±0.02 vs 0.32±0.04),开臂停留时间延长(78.33±9.29 min vs 41.15±9.64 min)。
- 与CLP组相比,CLP+Fisetin组海马神经元排列更有序、胞质深染减少、核固缩减少、神经元丢失减少、炎症细胞减少;铁离子沉积减少,脑组织铁离子和MDA含量降低[铁离子(μg/g):151.27±14.90 vs 224.69±17.64;MDA(μmol/g):470.0±44.3 vs 709.3±65.4]。
- 与CLP组相比,CLP+Fisetin组TNF-α和S100β表达显著降低(TNF-α/GAPDH:0.651±0.060 vs 0.896±0.022;S100β/GAPDH:0.685±0.032 vs 0.902±0.014),Nrf2、HO-1和GPX4表达显著升高(Nrf2/GAPDH:0.708±0.108 vs 0.316±0.112;HO-1/GAPDH:0.694±0.022 vs 0.538±0.024;GPX4/GAPDH:0.620±0.170 vs 0.317±0.039)。所有差异均有统计学意义(均P<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(大鼠CLP脓毒症模型)。
- 作者结论:非瑟酮预处理可通过Nrf2/HO-1/GPX4通路抑制铁死亡、减轻脓毒症相关脑损伤。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文为雄性SD大鼠CLP脓毒症模型的临床前研究,非瑟酮50 mg×kg⁻¹×d⁻¹灌胃预处理5天的方案不能直接外推为临床推荐。
- 作者认为非瑟酮预处理可通过Nrf2/HO-1/GPX4通路抑制铁死亡、减轻脓毒症相关脑损伤。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To observe the protective effect of Fisetin on sepsis-associated brain injury and explore its possible mechanism from the perspective of ferroptosis.
METHODS: Sprague-Dawley (SD) rats (6-8-week-old male) were randomly divided into three groups: sham operation group (Sham group), colonic ligation and puncture (CLP) induced sepsis model group (CLP group) and Fisetin preprocessing group (CLP+Fisetin group), with 18 rats in each group (12 for observing survival rate and 6 for indicator testing). The CLP+Fisetin group was given Fisetin solution 50 mg×kg-1×d-1 by gavage continuously for 5 days before CLP, with dimethyl sulfoxide (DMSO) as the solute, while Sham group and CLP group were given the same dose of DMSO. The model was established at 2 hours after the last gavage. The general condition of each group of rats were observed, and the 10-day mortality were record. The behavioral testing (new object recognition experiment, elevated cross maze experiment) were performed after 7 days of modeling. After 24 hours of modeling, nerve reflex scoring was performed, and then the rats were euthanized and brain tissue was collected. The pathological changes of brain tissue were observed under a microscope by hematoxylin-eosin (HE) staining, the deposition of iron ion in brain tissue was observed by Prussian blue staining. The content of iron in brain tissue was determined by tissue iron kit, and the content of malondialdehyde (MDA) in brain tissue was determined by colorimetry. The expressions of tumor necrosis factor-α (TNF-α), neuron damage marker S100β, nuclear factor E2-related factor 2 (Nrf2), heme oxygenases-1 (HO-1) and glutathione peroxidase 4 (GPX4) were detected by Western blotting.
RESULTS: On day 10 post-operation, 12, 3, and 7 animals survived in the Sham group, CLP group, and CLP+Fisetin group, respectively. Compared with the Sham group, rats in the CLP group showed significantly decreased nerve reflex score, new object discrimination index and open arm dwell time. HE staining showed arranged disorderly of neuronal cells, cytoplasm deep staining, nuclear condensation, unclear structures, neuron loss, and significant inflammation in the hippocampus in the hippocampus. Prussian blue staining showed iron ion deposition in the brain tissue. The contents of iron and MDA in brain tissue were elevated, and the expressions of TNF-α and S100β were up-regulated, while the expressions of Nrf2, HO-1, and GPX4 were down-regulated. Compared with the CLP group, the CLP+Fisetin group showed significantly increased neurological reflex score (7.33±1.15 vs. 4.67±1.53), improved new object discrimination index (0.44±0.02 vs. 0.32±0.04), and longer open arm dwell time (minutes: 78.33±9.29 vs. 41.15±9.64). Neuronal cells in the hippocampus were more organized, with less cytoplasmic staining, nuclear condensation, reduced neuronal loss, and fewer inflammatory cells. Iron ion deposition was reduced, and the contents of iron ions and MDA in brain tissue were decreased [iron ion (μg/g): 151.27±14.90 vs. 224.69±17.64, MDA (μmol/g): 470.0±44.3 vs. 709.3±65.4]. The expressions of TNF-α and S100β were significantly decreased (TNF-α/GAPDH: 0.651±0.060 vs. 0.896±0.022, S100β/GAPDH: 0.685±0.032 vs. 0.902±0.014), while the expressions of Nrf2, HO-1, and GPX4 were significantly increased (Nrf2/GAPDH: 0.708±0.108 vs. 0.316±0.112, HO-1/GAPDH: 0.694±0.022 vs. 0.538±0.024, GPX4/GAPDH: 0.620±0.170 vs. 0.317±0.039). All differences were statistically significant (all P < 0.05).
CONCLUSION: Fisetin pretreatment can inhibit ferroptosis and reduce sepsis-associated brain injury by Nrf2/HO-1/GPX4 pathway.
参考来源
- Sun R, Zhou J, Jiao Y, et al. [Fexolone inhibits neuronal ferroptosis through the Nrf2/HO-1/GPX4 pathway to alleviates sepsis-associated brain injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40819945. doi:10.3760/cma.j.cn121430-20241231-01080
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。